Heparin: Mechanism of Action, Pharmacokinetics, Dosing Considerations, Monitoring, Efficacy, and Safety
Authors:
- Jack HirshJHJack Hirsh
- James E. DalenJDJames E. Dalen
- Daniel DeykinDDDaniel Deykin
- Leon TollerLTLeon Toller
- Leon PollerLPLeon Poller
Abstract
No abstract availableKeywords
This publication has 169 references indexed in Scilit:
- Plasminogen activator italian multicenter study (PAIMS): Comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-pa) with intravenous streptokinase in acute myocardial infarctionJACC, 1989
- The Antithrombotic Activity and Pharmacokinetics of Enoxaparine, A Low Molecular Weight Heparin, In Humans Given Single Subcutaneous Doses of 20 to 80 mgThe Journal of Clinical Pharmacology, 1988
- Activation of heparin cofactor II by heparin oligosaccharidesBiochemical and Biophysical Research Communications, 1988
- Role of heparin after intravenous thrombolytic therapy for acute myocardial infarctionThe American Journal of Cardiology, 1987
- HEPARIN DOSES AND MAJOR BLEEDINGSThe Lancet, 1986
- Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activityBiochemical and Biophysical Research Communications, 1983
- TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA WITH THROMBOSIS BY NEW HEPARINOIDThe Lancet, 1983
- Highly active heparin species with multiple binding sites for antithrombinBiochemical and Biophysical Research Communications, 1979
- Anticoagulant activity of heparin: Separation of high‐activity and low‐activity heparin species by affinity chromatography on immobilized antithrombinFEBS Letters, 1976
- EFFICACY OF LOW-DOSE HEPARIN IN PREVENTION OF EXTENSIVE DEEP-VEIN THROMBOSIS IN PATIENTS UNDERGOING TOTAL-HIP REPLACEMENTThe Lancet, 1976